间歇性θ爆发刺激(iTBS)的抗抑郁效应:一项随机双盲假对照试验的研究方案
本方案描述一项单中心、双盲、随机安慰剂对照临床试验,纳入96例22-65岁至少中度抑郁的门诊患者,前瞩性接受每日一次共10次活性或假iTBS刺激左侧DLPFC,评估抗抑郁效应及临床、认知、脑影像和遗传因素与疗效变异的关系。首例受试者于2022年6月4日入组,研究预计2027年12月完成,已在ClinicalTrials.gov注册(NCT05516095)。
要点
- iTBS刺激左侧DLPFC已被显示在治疗抑郁方面与传统rTMS方案同等有效且安全。
- 本试验纳入至少中度抑郁(MADRS评分≥20)的门诊患者,接受10次每日一次的活性或假iTBS。
- 试验将评估基线临床、认知、脑影像和遗传指标与iTBS抗抑郁效应变异的关系。
核心结论
- 本试验旨在研究10次iTBS方案对中度抑郁门诊患者的抗抑郁效应,并探索可解释iTBS后抑郁症状减轻及治疗反应较差的因素。
研究设计与样本
- 单中心、双盲、随机安慰剂对照临床试验,前瞩性纳入96例22-65岁至少中度抑郁(MADRS评分≥20)的门诊患者,参与者可为任意程度治疗抵抗。
- 参与者接受每日一次共10次活性或假iTBS刺激左侧DLPFC,经神经导航系统定位。
- 刺激前进行安全性筛查、简要诊断评估、脑源性神经营养因子、5-HTTLPR和5-HT1A基因分析及脑MRI评估,刺激前和10次刺激后实施神经心理学测试和问卷,末次刺激后4周随访。
主要发现
- 首例受试者于2022年6月4日入组,研究预计2027年12月完成。
- 试验获挪威北部医学与健康科学区域伦理委员会批准,项目编号228765,按照良好临床实践和rTMS治疗已发表安全指南实施。
- 试验在ClinicalTrials.gov注册(NCT05516095),于2022年8月25日回顾性注册。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intermittent theta burst stimulation (iTBS) when applied over the left dorsolateral prefrontal cortex (DLPFC) has been shown to be equally effective and safe to treat depression compared to traditional repetitive transcranial magnetic stimulation (rTMS) paradigms. This protocol describes a funded single-centre, double-blind, randomized placebo-controlled, clinical trial to investigate the antidepressive effects of iTBS and factors associated with an antidepressive response. METHODS: In this trial, outpatients (N = 96, aged 22-65 years) meeting the diagnostic criteria for at least moderate depression (Montgomery and Aasberg Depression Rating Scale score ≥ 20) will be enrolled prospectively and receive ten, once-a-day sessions of either active iTBS or sham iTBS to the left DLPFC, localized via a neuronavigation system. Participants may have any degree of treatment resistance. Prior to stimulation, participants will undergo a thorough safety screening and a brief diagnostic assessment, genetic analysis of brain-derived neurotropic factor, 5-HTTLPR and 5-HT1A, and cerebral MRI assessments. A selection of neuropsychological tests and questionnaires will be administered prior to stimulation and after ten stimulations. An additional follow-up will be conducted 4 weeks after the last stimulation. The first participant was enrolled on June 4, 2022. Study completion will be in December 2027. The project is approved by the Regional Ethical Committee of Medicine and Health Sciences, Northern Norway, project number 228765. The trial will be conducted according to Good Clinical Practice and published safety guidelines on rTMS treatment. DISCUSSION: The aims of the present trial are to investigate the antidepressive effect of a 10-session iTBS protocol on moderately depressed outpatients and to explore the factors that can explain the reduction in depressive symptoms after iTBS but also a poorer response to the treatment. In separate, but related work packages, the trial will assess how clinical, cognitive, brain imaging and genetic measures at baseline relate to the variability in the antidepressive effects of iTBS. TRIAL REGISTRATION: ClinicalTrials.gov NCT05516095. Retrospectively registered on August 25, 2022.
引用
- Ørbo MC, Grønli OK, Larsen C, et al. The antidepressant effect of intermittent theta burst stimulation (iTBS): study protocol for a randomized double-blind sham-controlled trial. Trials. 2023. PMID: 37784199. doi:10.1186/s13063-023-07674-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。